News on lab-developed tests and emerging diagnostic technologies.
The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for patients who had not been in remission for five years and who had not been taking tamoxifen.
The approval expands the firm's product range now available to European customers.
In a rapidly growing industry where 14 new genetic tests are launched daily, tracking utilization and payment is increasingly difficult, Concert Genetics' report says.
The five-year-old firm recently completed a clinical trial of the real-time PCR-based test, called ProALL-BM, on patients from a European National Registry Study.
The partnership will allow Serosep's customers to benefit from standardized diagnostic interpretation supported by artificial intelligence and automation.
